Tokyo, Dec. 4 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059954) titled 'Study on the Diagnostic Utility of the CD56/CD3 Ratio in Gastrointestinal Mucosal Lymphocytes for GVHD after Hematopoietic Stem Cell Transplantation' on Dec. 3.
Study Type:
Observational
Primary Sponsor:
Institute - Okayama University Hospital
Condition:
Condition - Patients after hematopoietic stem cell transplantation
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify whether the CD56/CD3 ratio of gastrointestinal mucosal lymphocytes is useful for diagnosing gastrointestinal GVHD in patients after hematopoietic stem cell transplantation
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - Patients who have undergone hematopoietic stem cell transplantation and are scheduled to undergo gastrointestinal endoscopy with biopsy
Key exclusion criteria - Women who are pregnant or may be pregnant
Target Size - 100
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2025 Year 11 Month 21 Day
Date of IRB - 2025 Year 11 Month 21 Day
Anticipated trial start date - 2025 Year 12 Month 03 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068552
Disclaimer: Curated by HT Syndication.
